<DOC>
	<DOCNO>NCT00857246</DOCNO>
	<brief_summary>This study intend evaluate feasibility treatment efficacy add antibody block epidermal growth factor ( EGF ) pathway neoadjuvant approach proven efficacy developed New York University .</brief_summary>
	<brief_title>Pre-operation Chemo Antibody Therapy Followed Surgical Resection Adjuvant Chemoradiation Gastric Cancer</brief_title>
	<detailed_description>The overall objective study development definitive treatment patient locally advanced gastric cancer . To end , trial evaluate feasibility treatment efficacy add antibody block EGF pathway neoadjuvant approach proven efficacy developed New York University ( NYU ) . The combination Irinotecan Cisplatin show synergistic active gastric carcinoma . This trial therefore build upon NYU previous experience neoadjuvant administration Irinotecan combine Cisplatin well report enhanced activity Irinotecan , Cisplatin External beam radiation combine Cetuximab develop novel neoadjuvant adjuvant approach treatment gastric gastro-esophageal junction ( GEJ ) cancer . The program include : 1 ) systemic combination Irinotecan , Cisplatin Cetuximab use induction , 2 ) follow potentially curative gastrectomy GEJ resection , 3 ) post-operative chemoradiation report Intergroup study addition Cetuximab .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients must sign approve informed consent . must histologically document untreated gastric/GEJ carcinoma ( clinical stage T3 N0 T4 , T N1N3 M0 ) Patients tumor tissue available assessment EGF receptor status immunohistochemistry ( IHC ) . Patients Performance Status 02 . Patients , 18 year old , must either child bear potential negative pregnancy test within 7 day treatment . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Bone marrow function : absolute neutrophil count ( ANC ) least 1,500/ul ; platelet least 100,000/ul . Renal function : creatinine great 1.5 x institutional upper limit normal ( ULN ) . The PT PTT within range normal value Hepatic function : bilirubin great 1.5 x ULN ; aspartate aminotransferase ( AST ) great 2.5 x ULN . Acute hepatitis know HIV . Active uncontrolled infection . Significant history uncontrolled cardiac disease ; i.e. , uncontrolled hypertension , unstable angina , congestive heart failure . Prior therapy affect target EGF pathway . Prior allergic reaction chimerized murine monoclonal antibody therapy document presence human antimouse antibody ( HAMA ) . Any concurrent chemotherapy indicate study protocol investigational agent ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stomach cancer</keyword>
	<keyword>biologics</keyword>
	<keyword>antibody</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>neoadjuvant therapy</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>combination therapy</keyword>
</DOC>